[1] Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumors of the breast. World Health Organization classification of tumors[M]. 4th ed. Lyon: IARC Press, 2012.
[2] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypesdealing with the diversity of breast cancer: highlight of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.
[3] Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J]. Nature, 2000, 406(6797): 747-752.
[4] Matkovic B, Juretic A, Separovic V, et al. Immunohistochemical analysis of ER, PR, HER2, CK5/6, p63 and EGFR antigen expression in medullary breast cancer[J]. Tumori, 2008, 94(6): 838844.
[5] Cheang MC, Chia SK, Voduc KD, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. Natl Cancer Insc, 2009, 101(10): 736-750.
[6] Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications[J]. Nat Rev Cancer, 2009, 9(2): 95-107.
[7] Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J]. J Clin Oncol, 2007, 25(33): 5287-5312.
[8] Calil LN, Igansi CN, Meurer L, et al. Chlamydia trachomatis and human papillomavirus coinfection: association with p16INK4a and Ki67 expression in biopsies of patients with preneoplastic and neoplastic lesions[J]. Braz J Infect Dis, 2011, 15(2): 126-131.
[9] DialloDanebrock R, Ting E, Gluz O, et al. Protein expression profiling in highrisk breast cancer patients treated with highdose or conventional dosedense chemotherapy[J]. Clin Cancer Res, 2007, 13(2 Pt 1): 488-497.
[10] RodríguezPinilla SM, Sarrió D, Honrado E, et al. Vimentin and laminin expression is associated with basallike phenotype in both sporadic and BRCA1associated breast carcinomas[J]. J Clin Pathol, 2007, 60(9): 1006-1012.
[11] Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-2502.
[12] CharafeJauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers[J]. Oncogene, 2006, 25 (15): 2273-2284.
[13] Li X, Guo M, Mori E, et al. Activation of caspase3 in molt4 cells by apoptosisinducing nucleosides from CD57(+)HLADR(bright) natural suppressor cell line[J]. Biochem Biophys Res Commun, 2000, 268(2): 514-520. |